Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jun 18;26(1):122.
doi: 10.1186/s13075-024-03353-2.

Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome

Javier Narváez  1 , Elena Cañadillas  2 , Iván Castellví  3 , Juan José Alegre  4 , Vanesa Vicens-Zygmunt  5 , Guadalupe Bermudo  5 , Paola Vidal-Montal  6 , María Molina Molina  5 , Joan Miquel Nolla  6
Affiliations
Observational Study

Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome

Javier Narváez et al. Arthritis Res Ther. .

Erratum in

Abstract

Objective: To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue therapy in patients with antisynthetase syndrome and progressive interstitial lung disease (ASS-ILD).

Methods: Multicentre observational retrospective longitudinal study of a cohort of patients with ASS-ILD that started treatment with RTX due to recurrent or ongoing progressive ILD despite therapy with glucocorticoids and immunosuppressants.

Results: Twenty-eight patients were analyzed. Examining the entire study population, before treatment with RTX the mean decline in %pFVC and %pDLCO from the ASS-ILD diagnosis to the initiation of RTX treatment (T0) was -6.44% and -14.85%, respectively. After six months of treatment, RTX reversed the decline in pulmonary function test (PFT) parameters: ∆%pFVC +6.29% (95% CI: -10.07 to 2.51; p=0.002 compared to T0) and ∆%pDLCO +6.15% (95% CI: -10.86 to -1.43; p=0.013). Twenty-four patients completed one year of therapy and 22 two years, maintaining the response in PFT: ∆%pFVC: +9.93% (95% CI: -15.61 to -4.25; p=0.002) and ∆%pDLCO: +7.66% (95% CI: -11.67 to -3.65; p<0.001). In addition, there was a significant reduction in the median dose of prednisone, and it could be suspended in 18% of cases. In 33% of patients who required oxygen therapy at the start of treatment, it could be discontinued. The frequency of adverse events reached 28.5% of cases.

Conclusion: Based on our results, RTX appears to be effective as rescue therapy in most patients with recurrent or progressive ASS-ILD unresponsive to conventional treatment. The use of RTX was well tolerated in the majority of patients.

Keywords: Antisynthetase syndrome; Progressive interstitial lung disease; Treatment; Rituximab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Evolution of the predicted forced vital capacity (%pFVC) and the predicted diffusing capacity for carbon monoxide corrected for haemoglobin (%pDLCO) before initiation of RTX and after 1 year of treatment
See this image and copyright information in PMC

References

    1. Opinc AH, Makowska JS. Antisynthetase syndrome - much more than just a myopathy. Semin Arthritis Rheum. 2021;51:72–83. - PubMed
    1. Marco JL, Collins BF. Clinical manifestations and treatment of antisynthetase síndrome. Best Pract Res Clin Rheumatol. 2020;34:101503. - PubMed
    1. Wang R, Zhao Y, Qi F, Wu X, Wang Y, Xu Y, et al. Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China. Clin Rheumatol. 2023;42:703–709. - PubMed
    1. Zhao N, Jiang W, Wu H, Wang P, Wang X, Bai Y, et al. Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease. Front Immunol. 2022;13:872615. - PMC - PubMed
    1. Gasparotto M, Gatto M, Saccon F, Ghirardello A, Iaccarino L, Doria A. Pulmonary involvement in antisynthetase syndrome. Curr Opin Rheumatol. 2019;31:603–610. - PubMed

Publication types

Supplementary concepts